| pubmed-article:20818444 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C0376545 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C0740394 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C0937932 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:20818444 | lifeskim:mentions | umls-concept:C1280519 | lld:lifeskim |
| pubmed-article:20818444 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:20818444 | pubmed:dateCreated | 2011-6-9 | lld:pubmed |
| pubmed-article:20818444 | pubmed:abstractText | Rasburicase was administered at a fixed dose of 3?mg to treat 287 episodes of elevated serum uric acid levels (>7?mg/dL) in 247 adult patients with hematological malignancies. The median total dose of 36??g/kg (range: 18-65) was a fraction of the recommended total pediatric dose of 0.75-1.0?mg/kg. The median change in uric acid levels at 24?h was -4.1?mg/dL (range: -12 to +1) and -45% (range: -95 to +9). Uric acid levels normalized at 24?h in 72% of patients. There was no relationship between the weight-based dose and uric acid decline. The only predictor of success was the baseline uric acid; the failure rate was 84% with baseline level >12?mg/dL and 18% if it was ? 12. Uric acid levels continued to decline beyond 24?h in most patients without additional treatment. Serum creatinine remained stable over 24?h, and declined over 48?h and 7 days. There was no relationship between the extent of reduction in uric acid levels and serum creatinine. We conclude that a single 3-mg dose of rasburicase, used with close monitoring, is sufficient to treat most adults with uric acid levels up to 12?mg/dL. | lld:pubmed |
| pubmed-article:20818444 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20818444 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20818444 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20818444 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20818444 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20818444 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20818444 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20818444 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20818444 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:20818444 | pubmed:issn | 1476-5365 | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:MehtaJJ | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:NewmanDD | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:LêMM | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:GreenbergDD | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:ZookJJ | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:CoyleKK | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:GoldOO | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:TrifilioS MSM | lld:pubmed |
| pubmed-article:20818444 | pubmed:author | pubmed-author:KosloskyMM | lld:pubmed |
| pubmed-article:20818444 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20818444 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:20818444 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20818444 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20818444 | pubmed:pagination | 800-5 | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:meshHeading | pubmed-meshheading:20818444... | lld:pubmed |
| pubmed-article:20818444 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20818444 | pubmed:articleTitle | Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. | lld:pubmed |
| pubmed-article:20818444 | pubmed:affiliation | Northwestern Memorial Hospital, and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. | lld:pubmed |
| pubmed-article:20818444 | pubmed:publicationType | Journal Article | lld:pubmed |
